Nuvectis Pharma Investor Presentation Deck
NXP800 Key Highlights
Precision Medicine
Approach
Focused Clinical &
Regulatory Strategy
Preclinical & Clinical
Data
Phase 1b
NuvectisPharma, Inc.
→ Discovered and optimized at the Institute of Cancer Research (ICR) in the UK
GCN2 kinase activator
* ARID1a loss is a marker for treatment sensitivity in ovarian, endometrial and gastric xenograft models
Fast Track Designation granted for the treatment of platinum resistant, ARID1A-mutated ovarian carcinoma
High prevalence of ARID1a mutation in Ovarian clear cell & endometrioid cancers: ~66% and 40% respectively
▪ ARID1a mutations very rare in high grade serous ovarian carcinoma
Orphan Drug Designation granted for the treatment of cholangiocarcinoma
■
→ Substantial tumor growth inhibition in multiple solid tumors; Recent preclinical data presentations (2023):
ESMO Gyne, AACR
Phase 1a PK/PD data supports doses selected for Phase 1b; selected two doses for testing in Phase 1b
In collaboration with the European Network of Gynecological Oncology Trial Groups (ENGOT)
and the Gynecology Oncology Group Foundation (GOG-F)
7View entire presentation